News Genome & Company

Stocks

A314130

KR7314130006

Biotechnology & Medical Research

End-of-day quote Korea S.E. 2026-10-21			5-day change	1st Jan Change
4,220.00 ^KRW	+0.12%		-11.16%	-38.66%

09-20	Genome & Company(KOSDAQ:A314130) added to S&P Global BMI Index	CI
08-14	Genome & Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

All News

Mentions Relevance

09-20	Genome & Company(KOSDAQ:A314130) added to S&P Global BMI Index	CI
08-14	Genome & Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
04-13	Genome & Company announced that it has received KRW 6.99999414 billion in funding	CI
04-02	Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding	CI
03-12	Genome & Company announced that it has received KRW 29.99998254 billion in funding from DongKoo Bio & Pharma Co., Ltd.	CI
25-09-21	Genome & Company(KOSDAQ:A314130) dropped from S&P Global BMI Index	CI
25-08-20	An undisclosed buyer agreed to acquire 40.12% stake in List Biotherapeutics, Inc. from Genome & Company for $19.1 million.	CI
25-07-10	Genome & Company announced that it has received KRW 25.7890592 billion in funding	CI
25-04-27	Genome & Company announced that it has received KRW 27.066097613 billion in funding from a group of investors	CI
25-04-23	Genome & Company announced that it expects to receive KRW 27.066097613 billion in funding from a group of investors	CI
25-04-23	Genome & Company announced that it expects to receive KRW 27.06426965 billion in funding	CI
25-04-23	Genome & Company agreed to acquire an additional 28.64% stake in List Biotherapeutics, Inc. from a group of shareholders for KRW 27.07 billion.	CI
24-07-18	Genome & Company announced that it has received KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd.	CI
24-07-16	Genome & Company announced that it expects to receive KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd.	CI
24-01-24	Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI	CI
23-05-19	Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial	CI
23-04-06	Genome & Company announced that it has received KRW 23 billion in funding from a group of investors	CI
23-04-04	Genome & Company announced that it expects to receive KRW 23 billion in funding from a group of investors	CI
22-09-01	Genome & Company announced that it has received KRW 34.34975035 billion in funding from a group of investors	CI
22-08-17	Genome & Company announced that it expects to receive KRW 34.34975035 billion in funding from a group of investors	CI
22-03-03	Genome and Company Announces Clinical Trial Collaboration with Merck & Co., Inc	CI
21-09-21	Microbiome CDMO, List Labs, Partners with Genome And Company, to Create Global Microbiome Research, Development, and Manufacturing Powerhouse	CI
21-09-20	Genome & Company(KOSDAQ:A314130) added to S&P Global BMI Index	CI
21-09-07	Genome & Company agreed to acquire a 60% stake in List Biological Laboratories, Inc. for $27 million.	CI
21-03-09	Genome and Company Signs Second Clinical Trial Collaboration and Supply Agreement (Phase 2) with Merck Kgaa, Darmstadt, Germany and Pfizer for Immuno-Oncology Microbiome Study	CI